Biogen Inc. (BIIB)
NASDAQ: BIIB · Real-Time Price · USD
188.24
+3.37 (1.82%)
At close: Mar 9, 2026, 4:00 PM EDT
188.24
0.00 (0.00%)
After-hours: Mar 9, 2026, 4:03 PM EDT
Biogen Employees
Biogen had 7,500 employees as of December 31, 2025. The number of employees decreased by 105 or -1.38% compared to the previous year.
Employees
7,500
Change (1Y)
-105
Growth (1Y)
-1.38%
Revenue / Employee
$1,318,747
Profits / Employee
$172,387
Market Cap
27.61B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7,500 | -105 | -1.38% |
| Dec 31, 2024 | 7,605 | 35 | 0.46% |
| Dec 31, 2023 | 7,570 | -1,155 | -13.24% |
| Dec 31, 2022 | 8,725 | -885 | -9.21% |
| Dec 31, 2021 | 9,610 | 510 | 5.60% |
| Dec 31, 2020 | 9,100 | 1,700 | 22.97% |
| Dec 31, 2019 | 7,400 | -400 | -5.13% |
| Dec 31, 2018 | 7,800 | 500 | 6.85% |
| Dec 31, 2017 | 7,300 | -100 | -1.35% |
| Dec 31, 2016 | 7,400 | 50 | 0.68% |
| Dec 31, 2015 | 7,350 | -200 | -2.65% |
| Dec 31, 2014 | 7,550 | 700 | 10.22% |
| Dec 31, 2013 | 6,850 | 900 | 15.13% |
| Dec 31, 2012 | 5,950 | 950 | 19.00% |
| Dec 31, 2011 | 5,000 | 150 | 3.09% |
| Dec 31, 2010 | 4,850 | 100 | 2.11% |
| Dec 31, 2009 | 4,750 | 50 | 1.06% |
| Dec 31, 2008 | 4,700 | 400 | 9.30% |
| Dec 31, 2007 | 4,300 | 550 | 14.67% |
| Dec 31, 2006 | 3,750 | 410 | 12.28% |
| Dec 31, 2005 | 3,340 | -926 | -21.71% |
| Dec 31, 2004 | 4,266 | 539 | 14.46% |
| Feb 20, 2004 | 3,727 | 2,732 | 274.57% |
| Jan 31, 2003 | 995 | 303 | 43.79% |
| Jan 31, 2002 | 692 | 199 | 40.37% |
| Jan 31, 2001 | 493 | 86 | 21.13% |
| Jan 31, 2000 | 407 | 42 | 11.51% |
| Jan 31, 1999 | 365 | 26 | 7.67% |
| Dec 31, 1997 | 339 | 71 | 26.49% |
| Dec 31, 1996 | 268 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 95,100 |
| Novartis AG | 75,267 |
| Pfizer | 75,000 |
| Merck & Co. | 75,000 |
| Sanofi | 74,846 |
| Novo Nordisk | 69,505 |
| GSK plc | 68,629 |
| Bristol-Myers Squibb Company | 32,500 |
BIIB News
- 4 days ago - Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences - GlobeNewsWire
- 4 days ago - The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome - Business Wire
- 7 days ago - Biogen Inc. (BIIB) Presents at TD Cowen 46th Annual Health Care Conference Transcript - Seeking Alpha
- 24 days ago - Biogen Inc. (BIIB) Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium Transcript - Seeking Alpha
- 25 days ago - Biogen Announces Board Chair Transition - GlobeNewsWire
- 4 weeks ago - Biogen Analysts Boost Their Forecasts After Upbeat Q4 Earnings - Benzinga
- 4 weeks ago - Biogen FY25 Earnings: Stable EPS, Amid Pressure From The Multiple Sclerosis Franchise - Seeking Alpha
- 4 weeks ago - Biogen Inc. (BIIB) Q4 2025 Earnings Call Transcript - Seeking Alpha